R52.2
Conditions
Interventions
Group 1: Fibromyalgia patients
Questionnaires (FIQ, SF36, HADS, PHQ4) and blood sampling before and after day clinic (day clinic duration: 4 weeks)
Group 2: Chronic musculoskelettal pain patients (nec
Sponsors
Klinik für Physikalische Medizin und Rehabilitation
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: diagnosis of fibromyalgia according to ACR criteria (patients) No pain in the last four weeks before participation in the study (healthy subjects) participation in the day clinic focus on osteoarthritis, back pain or osteoporosis of the Clinic and Polyclinic for Physical Medicine and Rehabilitation and continuous pain VAS>3/ 10 on the visual analog scale (VAS) from 0-10 for more than 3 months (patient control group) maturity willingness to give a blood sample as part of the study wllingness to refrain from taking NSAIDs and COX inhibitors from 1 week prior to and during the observation period no intake of paracetamol and metamizole up to 3 days before the blood samples (patient diary)
Exclusion criteria
Exclusion criteria: Age under 18 years lack of compliance Pregnancy or breastfeeding period (anamnestic clarification according to CPMP/ICH/286/95) diabetes mellitus requiring insulin surgery in the last 3 months severe heart disease severe lung diseases severe kidney disease chronic inflammatory diseases endocrine disorders diseases that, due to their severity, coupe an assessment of the quality of life limitations caused by fibromyalgia schizophrenia, dementia severe coagulation disorders immunosuppression
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eicosanoid levels | — |
Secondary
| Measure | Time frame |
|---|---|
| cytokine levels, results of FIQ, SF-36, HADS and PHQ4 | — |
Countries
Germany
Contacts
Public ContactSybille Kramer
Klinik und Poliklinik für Physikalische Medizin und Rehabilitation
Outcome results
None listed